{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Morgan RD"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["1919-1927"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11628596"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["131(12)"],"pubmed_abstract":["<h4>Background</h4>High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response score (CRS). We investigated whether germline BRCA1/2 (gBRCA1/2) genotype associated with omental CRS phenotype.<h4>Methods</h4>A retrospective study of patients with newly diagnosed FIGO stage IIIC/IV HGSOC prescribed NACT and tested for gBRCA1/2 pathogenic variants (PVs) between September 2017 and December 2022 at The Christie Hospital. The Cox proportional hazards model evaluated the association between survival and key clinical factors. The chi-square test assessed the association between CRS3 (no/minimal residual tumour) and gBRCA1/2 status.<h4>Results</h4>Of 586 eligible patients, 393 underwent DPS and had a CRS reported. Independent prognostic factors by multivariable analysis were gBRCA1/2 status (PV versus wild type [WT]), CRS (3 versus 1 + 2), surgical outcome (complete versus optimal/suboptimal) and first-line poly (ADP-ribose) polymerase-1/2 inhibitor maintenance therapy (yes versus no) (all P < 0.05). There was a non-significant trend for tumours with a gBRCA2 PV having CRS3 versus WT (odds ratio [OR] = 2.13, 95% confidence intervals [CI] 0.95-4.91; P = 0.0647). By contrast, tumours with a gBRCA1 PV were significantly less likely to have CRS3 than WT (OR = 0.35, 95%CI 0.14-0.91; P = 0.0291).<h4>Conclusions</h4>Germline BRCA1/2 genotype was not clearly associated with superior omental CRS. Further research is required to understand how HGSOC biology defines CRS."],"journal":["British journal of cancer"],"pubmed_title":["Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer."],"pmcid":["PMC11628596"],"funding_grant_id":["NIHR203308"],"pubmed_authors":["Morgan RD","Netto D","Taylor SS","Carrot A","Winter-Roach B","Burghel GJ","Desai S","Barnes BM","Jayson GC","Spurgeon L","Evans DGR","Hasan J","Mitchell C","Edmondson RJ","Salih Z","Schlecht H","Wang X","You B","Shaw J","Clamp AR"],"additional_accession":[]},"is_claimable":false,"name":"Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.","description":"<h4>Background</h4>High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response score (CRS). We investigated whether germline BRCA1/2 (gBRCA1/2) genotype associated with omental CRS phenotype.<h4>Methods</h4>A retrospective study of patients with newly diagnosed FIGO stage IIIC/IV HGSOC prescribed NACT and tested for gBRCA1/2 pathogenic variants (PVs) between September 2017 and December 2022 at The Christie Hospital. The Cox proportional hazards model evaluated the association between survival and key clinical factors. The chi-square test assessed the association between CRS3 (no/minimal residual tumour) and gBRCA1/2 status.<h4>Results</h4>Of 586 eligible patients, 393 underwent DPS and had a CRS reported. Independent prognostic factors by multivariable analysis were gBRCA1/2 status (PV versus wild type [WT]), CRS (3 versus 1 + 2), surgical outcome (complete versus optimal/suboptimal) and first-line poly (ADP-ribose) polymerase-1/2 inhibitor maintenance therapy (yes versus no) (all P < 0.05). There was a non-significant trend for tumours with a gBRCA2 PV having CRS3 versus WT (odds ratio [OR] = 2.13, 95% confidence intervals [CI] 0.95-4.91; P = 0.0647). By contrast, tumours with a gBRCA1 PV were significantly less likely to have CRS3 than WT (OR = 0.35, 95%CI 0.14-0.91; P = 0.0291).<h4>Conclusions</h4>Germline BRCA1/2 genotype was not clearly associated with superior omental CRS. Further research is required to understand how HGSOC biology defines CRS.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-26T23:09:59.848Z","creation":"2025-04-06T17:30:48.851Z"},"accession":"S-EPMC11628596","cross_references":{"pubmed":["39550490"],"doi":["10.1038/s41416-024-02874-6"]}}